Sjögren's disease & overlap diseases
Identification of new candidate drugs for primary Sjögren’s syndrome using a drug repurposing transcriptomic approach
Authors' conclusion
This first drug repositioning transcriptomic approach in SS confirms the interest of targeting interferons and identifies histone deacetylases and PI3K inhibitors as potential therapeutic targets.
Study context
- Population
- Peripheral blood transcriptomes of patients with pSS and healthy controls from five independent studies
- Participants
- 1,008 participants5 independent studies
- Exposure
- pSS vs healthy controls, peripheral blood transcriptomes compared with drug, knock-in and knock-down gene signatures
- pSSn = 868
- Healthy controlsn = 140reference
- Outcome
- Commonalities between pSS signatures and drug or gene perturbation signatures
Methodological detailsConnectivity Map database analysis, two cohorts and three public databases
- Connectivity Map database analysis
- Two cohorts and three public databases
Main finding
As reported in the abstract
Potential candidate drugs, with histone deacetylases and PI3K inhibitors among the most significantly associated
11
Knock-in genes associated with a pSS-like profile
12
Knock-down genes associated with a pSS-revert profile
23
Interferon-regulated genes among those genes
28/35, 80%
Observational data: associations, not effects.
Original publication
Identification of new candidate drugs for primary Sjögren’s syndrome using a drug repurposing transcriptomic approach. Rheumatology (Oxford). Published 3 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →